Engineered Immune Cells for Senescent Cell Clearance

Cellular senescence is a stress-associated state usually characterized by durable cell-cycle arrest and context-dependent changes in cell structure, metabolism, and secretion. No single marker is sufficient to identify the state in every cell type or tissue. [1] Senescent cells can support tumour suppression and tissue repair, but their persistent accumulation can also disrupt tissue environments. [1] [3]

Mouse studies using genetically inducible ablation systems provided evidence that removing selected p16^Ink4a-expressing cells can delay several age-associated disorders. These systems are an experimental proof of principle, not a directly transferable human treatment. [2] Engineered immune cells pursue a related goal through recognition of extracellular targets rather than an artificial intracellular suicide switch. [6]

Why Use Immune Cells?

Immune surveillance already contributes to senescent-cell control. In cell and mouse experiments, natural killer (NK) cells recognized senescence-associated NKG2D ligands and preferentially killed some senescent targets. [4] Human fibroblast experiments also identified DPP4 as a surface protein that could support antibody-dependent killing by NK cells under the tested conditions. [5]

Engineering is intended to make that recognition more deliberate. A chimeric antigen receptor (CAR) gives an immune cell a synthetic receptor that binds a selected surface antigen and activates cellular killing. In senolytic CAR T-cell studies, the chosen antigen was urokinase-type plasminogen activator receptor (uPAR), which was elevated across several experimentally induced senescent-cell models. [6]

The uPAR CAR T-Cell Evidence

In 2020, Amor and colleagues reported that uPAR-directed CAR T cells preferentially eliminated uPAR-positive senescent cells in culture. In mice, the cells reduced senescent-cell burden and fibrosis in chemically and diet-induced liver injury models; they also improved survival in a lung-cancer model treated with a senescence-inducing drug combination. [6] These experiments addressed specific disease models and did not test human ageing. [6]

A 2024 study extended the same targeting strategy to aged mice and mice fed a high-fat diet. A single administration of uPAR CAR T cells produced persistent cells and was associated with improved glucose tolerance, lower fasting glucose, and better exercise capacity in the reported experiments. Treatment given to young mice before high-fat feeding also reduced later metabolic dysfunction. [7] These findings show durability and prevention within particular mouse protocols; they do not demonstrate lifespan extension or clinical benefit in people. [7]

Target Selection Is the Central Problem

Senescence is heterogeneous: the phenotype varies with cell lineage, inducing stress, tissue, and time. Consensus guidance therefore recommends combinations of markers rather than a universal single-marker definition. [1] DPP4 was enriched on the surface of replicatively senescent human diploid fibroblasts in one study, while uPAR was identified across a different panel of senescence models. Neither result establishes universal coverage or exclusive expression on senescent cells. [5] [6]

For an engineered cytotoxic cell, imperfect specificity has two distinct consequences. A target absent from some senescent populations leaves those cells untouched, while expression on healthy cells can create on-target damage outside the intended population. The uPAR studies evaluated this balance in defined mouse models, but human tissue distribution, disease context, and longer follow-up could alter it. [6] [7]

T Cells, NK Cells, and the Meaning of “Engineered”

Safety and Control

CAR T-cell toxicities are well documented in oncology, although their frequency depends on the CAR, antigen, disease burden, and clinical setting. In a multicentre study of CD19-directed CAR T cells for lymphoma, serious adverse events included cytokine-release syndrome, neurological events, prolonged cytopenias, and infections. [8] Those incidence estimates cannot be transferred directly to uPAR CAR T cells, but they identify safety domains that a senolytic product would need to evaluate. [8]

Persistence is also a trade-off rather than an automatic advantage. Long-lived cells could provide continuing surveillance, as observed in the 2024 mouse study, but they could also prolong unintended activity if the target is present on non-senescent cells. [7] Because transient senescence contributes to wound repair, the timing and degree of clearance may matter as much as the target itself. [3]

Evidence Quality and Interpretation

The strongest evidence is mechanistic and preclinical. Two studies from the same research programme demonstrate target recognition, senescent-cell reduction, and functional effects across several mouse models. [6] [7] Independent findings that NK cells can recognize senescence-associated surface changes support the broader biological premise of immune surveillance. [4] [5]

Important uncertainties remain: whether uPAR provides adequate selectivity in diverse human tissues, whether other antigens or multi-antigen logic would improve discrimination, how engineered cells would behave in older or medically complex people, and whether changes in senescent-cell markers would lead to durable clinical benefit. The cited efficacy studies do not answer these human translational questions. [6] [7]

What the Research Does Not Establish

• It does not show that every senescent cell should be removed; transient senescence can aid wound repair. [3]
• It does not show that uPAR or DPP4 uniquely identifies senescence in all human tissues. [1] [5] [6]
• It does not establish that CAR T-cell results in mice predict safety or efficacy in humans. [6] [7]
• It does not establish lifespan extension: the ageing-mouse CAR T-cell study reported metabolic and exercise outcomes, not a lifespan experiment. [7]

Summary

Engineered immune-cell senolysis is a targeted extension of the immune system's existing role in senescent-cell surveillance. uPAR CAR T cells have produced sustained clearance and functional effects in several mouse models, making them a substantive proof of concept. [4] [6] [7] The same evidence also defines the limits of the field: antigen specificity is incomplete, beneficial senescence must be preserved where possible, and human safety and clinical benefit remain untested by these studies. [1] [3] [6] [7]

References

1. Gorgoulis, V. et al. "Cellular Senescence: Defining a Path Forward." Cell (2019). https://doi.org/10.1016/j.cell.2019.10.005
2. Baker, D. J. et al. "Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders." Nature (2011). https://doi.org/10.1038/nature10600
3. Demaria, M. et al. "An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA." Developmental Cell (2014). https://doi.org/10.1016/j.devcel.2014.11.012
4. Sagiv, A. et al. "NKG2D ligands mediate immunosurveillance of senescent cells." Aging (2016). https://doi.org/10.18632/aging.100897
5. Kim, K. M. et al. "Identification of senescent cell surface targetable protein DPP4." Genes & Development (2017). https://doi.org/10.1101/gad.302570.117
6. Amor, C. et al. "Senolytic CAR T cells reverse senescence-associated pathologies." Nature (2020). https://doi.org/10.1038/s41586-020-2403-9
7. Amor, C. et al. "Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction." Nature Aging (2024). https://doi.org/10.1038/s43587-023-00560-5
8. Schuster, S. J. et al. "Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma." New England Journal of Medicine (2019). https://doi.org/10.1056/NEJMoa1804980
9. Kim, K. et al. "Enhanced co-culture and enrichment of human natural killer cells for the selective clearance of senescent cells." Aging (2022). https://doi.org/10.18632/aging.203931